Renalytix plc
("Renalytix" or the
"Company")
Director/PDMR dealings
LONDON and NEW YORK, 11 December 2024
- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), an
artificial intelligence-enabled in vitro diagnostics company,
focused on optimizing clinical management of kidney disease to
drive improved patient outcomes and advance value-based
care, announces the
following Director dealings.
On 5 December, certain investment vehicles connected with Christopher Mills,
Non-Executive Chairman, sold 48,601 ordinary shares of £0.0025 each
("Ordinary Shares") in the Company at a price of £0.07 per Ordinary
Share on behalf of a private client account. Following this
transaction, Christopher Mills and the investment vehicles
connected with him are interested in 14,561,345 Ordinary Shares
representing 4.4% of the issued share capital of the
Company.
On 10 December, James McCullough,
Chief Executive Officer, bought 25,000 ordinary shares of £0.0025
each ("Ordinary Shares") in the Company at a price of £0.085 per
Ordinary Share. Following this transaction, James McCullough is
interested in 3,242,096 Ordinary Shares representing 0.98% of the issued share capital
of the Company.
Howard Doran, President of
Renalytix, bought 50,000 ordinary shares of £0.0025 each ("Ordinary
Shares") in the Company at a price of £0.089 per Ordinary
Share. Following this transaction, Howard
Doran is interested in 100,000 Ordinary Shares
representing 0.03% of the issued share capital of the
Company.
Julian Baines, Executive Chairman of
Renalytix, also bought 23,000 ordinary shares of £0.0025 each
("Ordinary Shares") in the Company at a price of £0.085 per
Ordinary Share. Following this transaction,
Julian Baines is interested in 1,848,700 Ordinary Shares
representing 0.56% of the issued share capital of the
Company.
For further information,
please contact:
|
Renalytix plc
|
www.renalytix.com
|
|
James McCullough, CEO
|
Via
Walbrook PR
|
|
|
|
|
Stifel (Nominated Adviser and Joint Broker)
|
Tel: 020
7710 7600
|
|
Nicholas Moore / Nick Harland / Ben
Good
|
|
|
|
|
|
Oberon Capital
(Joint Broker)
|
Tel: 020
3179 5300
|
|
Mike Seabrook / Nick Lovering
|
|
|
|
|
|
Walbrook PR Limited
|
Tel: 020
7933 8780 or renalytix@walbrookpr.com
|
|
Paul McManus / Alice Woodings
|
Mob: 07980 541 893 / 07407
804 654
|
|
|
|
|
CapComm Partners
|
|
|
Peter DeNardo
|
Tel:
415-389-6400 or investors@renalytix.com
|
About
Renalytix
Renalytix (LSE: RENX) (OTCQB: RNLXY) is an in-vitro
diagnostics and laboratory services company that is the global
founder and leader in the new field of bioprognosis™ for kidney
health. The leadership team, with a combined 200+ years of
healthcare and in-vitro diagnostic experience, has designed its
KidneyIntelX laboratory developed test to enable risk assessment
for rapid progressive decline in kidney function in adult patients
with T2D and early CKD (stages 1-3). We believe that by
understanding how disease will progress, patients and providers can
take action early to improve outcomes and reduce overall health
system costs. For more information, visit www.renalytix.com
Notification and
public disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Harwood Capital LLP*
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Christopher Mills, Non-Executive
Chairman, Chief Investment Officer of
Harwood
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.07
|
48,601
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
48,601
|
|
- Price
|
£0.07
|
|
|
|
|
e)
|
Date of the transaction
|
5 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
James McCullough
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
CEO
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.085
|
25,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
25,000
|
|
- Price
|
£0.085
|
|
|
|
|
e)
|
Date of the transaction
|
10 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Howard Doran
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
President of Renalytix
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.089
|
50,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
50,000
|
|
- Price
|
£0.089
|
|
|
|
|
e)
|
Date of the transaction
|
10 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Julain Baines
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Executive Chairman
|
|
b)
|
Initial notification
/Amendment
|
Initial Notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Renalytix plc
|
|
b)
|
LEI
|
213800NTOH3FK3WER551
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Ordinary shares of £0.0025
each
|
|
|
|
|
Identification code
|
GB00BYWL4Y04
|
|
|
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares
|
|
c)
|
Price(s) and volume(s)
|
|
|
|
|
|
|
|
Price(s)
|
Volume(s)
|
|
|
|
|
£0.085
|
23,000
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
23,000
|
|
- Price
|
£0.085
|
|
|
|
|
e)
|
Date of the transaction
|
10 December 2024
|
|
f)
|
Place of the transaction
|
London Stock Exchange, AIM
|
*Christopher Mills is partner and
Chief Investment Officer of Harwood Capital LLP. Harwood Capital
LLP is Investment Manager to North Atlantic Smaller Companies
Investment Trust plc and investment adviser to Oryx International
Growth Fund Limited. Christopher's shareholding is made up of
ordinary shares held by North Atlantic Smaller Companies Investment
Trust PLC, Oryx International Growth Fund Limited and Harwood
Capital LLP.